Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Names New Chairman, Acting CEO

NEW YORK (GenomeWeb News) – A day after its chairman's re-election was blocked and its CEO resigned, Genetic Technologies named a new chairman and acting CEO today.

The Australian firm named Mal Brandon, a current board member, as its new chairman of the board of directors. The firm also said that COO Alison Mew has been named acting CEO.

The appointments come a day after the firm's annual general meeting, at which Chairman Mel Bridges and Director Huw Jones were not re-elected to the firm's board — apparently due to the efforts of Founder Mervyn Jacobson, who used his 29 percent stake to block their re-election. Following the meeting, CEO Paul MacLeman, Director Greg Brown, and VP of Legal and Corporate Development David Sparling all resigned.

The firm did not respond to an email from GenomeWeb Daily News seeking further information and comment.

"The board is confident that the company will continue to build on the solid foundation that has been created and looks forward to further expansion of its US operations and its global licensing programs," Brandon said in a statement issued today.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.